Background: Presently, varied case reports demonstrated an increase or decrease in blood concentration of diverse conventional drugs, often co-administered with edible fruits, spices, or vegetables. The overarching aim of this research is to elucidate the fluctuations in tacrolimus (TAC) blood concentration on the consumption of pomegranate rind extract (PRE). Methods: A pharmacokinetic (PK) study was conducted with two groups, vis-a-vis PRE + TAC (3mg/kg) and TAC (3mg/kg) alone groups. An experimental study was conducted in three different manners: Single-dose (S) PRE (200mg/kg), 7-day repetitive (7-R) PRE (200mg/kg) dosing, and multiple (M) PRE doses (100, 200, 400, and 800mg/kg). All the blood samples (approximately 300μl) were drawn at different time intervals, i.e., 30min, 1, 2, 4, 8, and 12h after oral administration of TAC (3mg/kg). The estimation of TAC in rat plasma was done using the hyphenated technique LC-MS/MS where the mass spectrometer used was a triple-stage quadrupole in multiple-reaction monitoring (MRM) mode. Results: The findings depict that in comparison with the TAC (3mg/kg) alone group with the 7-day repetitive (7-R) PRE (200mg/kg) dosing, the Cmax was found to be 9.03 ± 1.21ng/ml; AUC from time zero to infinity (AUC0-∞), 61.91 ± 17.37ngh/ml, while the TAC (3mg/kg) + PRE group exhibited an increase in PK parameters of TAC (Cmax 22.48 ± 3.07ng/ml; AUC0-∞ 153.08 ± 13.24ngh/ml). The authors further investigated in what manner the PRE affects the PK of TAC in animals. For this, docking studies with major phytoconstituents present in the PRE with CYP3A4 isoenzyme were carried out. Ellagitannins (dock score, -11.64) and punicalagin (dock score, -10.68) were again used for molecular simulation studies with TAC. To validate our findings, a CYP3A4 inhibitory in vitro assay was conducted. Conclusion: Based on the integrated in vivo and in silico studies, we concluded that pomegranate rind extract interacts strongly with CYP isoenzyme and is therefore responsible for the altered PK profile of TAC.